Amortization expense related to acquired technology was $3.0 million and $4.2 million for the three months ended September 30, 2026 and 2025, respectively, and $13.6 million and $12.6 million for the nine months ended September 30, 2026 and 2025, respectively. Amortization expense is included in the amortization of acquired technology and other intangible assets expense line item on the Consolidated Statements of Income and is expected to be $3.0 million for the three months ending December 31, 2026, $12.2 million in each of the years ending December 31, 2027 and 2028, $12.1 million in each of the years ending December 31, 2029 and 2030, and $41.5 million in total thereafter.
Merck KGaA Patent Acquisitions
In April 2023, UDC Ireland entered into a Patent Sale and License Agreement with Merck KGaA. Under this agreement, Merck KGaA sold to UDC Ireland all of its rights, title and interest to over 550 of its owned and licensed OLED-related patents and patent applications in exchange for a cash payment of $66.0 million. The Patent Sale and License Agreement contains customary representations, warranties and covenants of the parties. UDC Ireland recorded the payment of $66.0 million as acquired technology, which is being amortized over a period of 10 years.
In October 2025, UDC Ireland entered into an Intellectual Property Sales Agreement with Merck KGaA. Under this agreement, UDC Ireland agreed to acquire from Merck KGaA all of its rights, title and interest to more than 300 of its OLED-related patents and patent applications in exchange for cash payments totaling $50.0 million. The Intellectual Property Sale Agreement contains customary representations, warranties and covenants of the parties. In November 2025, an initial payment of $10.0 million was made toward the purchase price and was included in other current assets on the Consolidated Balance Sheets as of December 31, 2025. In January 2026 the transaction closed and UDC Ireland recorded the total cash payments of $50.0 million as acquired technology, which is being amortized over a period of 10 years.
BASF Patent Acquisition
On June 28, 2016, UDC Ireland entered into and consummated an IP Transfer Agreement with BASF. Under the IP Transfer Agreement, BASF sold to UDC Ireland all of its rights, title and interest to certain of its owned and co-owned intellectual property rights relating to the composition, development, manufacture and use of OLED materials, including OLED lighting and display stack technology, as well as certain tangible assets. The intellectual property includes knowhow and more than 500 issued and pending patents in the area of phosphorescent materials and technologies. These assets were acquired in exchange for a cash payment of €86.8 million ($95.8 million). In addition, UDC Ireland also took on certain rights and obligations under three joint research and development agreements to which BASF was a party. The IP Transfer Agreement also contains customary representations, warranties and covenants of the parties. UDC Ireland recorded the payment of €86.8 million ($95.8 million) and acquisition costs incurred of $217,000 as acquired technology, which was being amortized over a period of 10 years.
Other Intangible Assets
As a result of the Adesis acquisition in June 2016, the Company recorded $16.8 million of other intangible assets, including $10.5 million assigned to customer relationships with a weighted average life of 11.5 years, $4.8 million to internally developed IP, processes and recipes with a weighted average life of 15 years, and $1.5 million to trade name and trademarks with a weighted average life of 10 years.
At September 30, 2026, these other intangible assets consist of the following (in thousands):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
September 30, 2026 |
|
|
|
Gross Carrying Amount |
|
|
Accumulated Amortization |
|
|
Net Carrying Amount |
|
Customer relationships |
|
$ |
10,520 |
|
|
$ |
(9,315 |
) |
|
$ |
1,205 |
|
Developed IP, processes and recipes |
|
|
4,820 |
|
|
|
(3,268 |
) |
|
|
1,552 |
|
Trade name/Trademarks |
|
|
1,500 |
|
|
|
(1,500 |
) |
|
|
— |
|
Other |
|
|
448 |
|
|
|
(225 |
) |
|
|
223 |
|
Total identifiable other intangible assets |
|
$ |
17,288 |
|
|
$ |
(14,308 |
) |
|
$ |
2,980 |
|
Under the current license agreement among the Company, Princeton and USC, the universities have granted the Company worldwide, exclusive license rights, with rights to sublicense, to make, have made, use, lease and/or sell products and to practice processes based on patent applications and issued patents arising out of research performed by the universities for the Company. The Company recorded royalty expense in connection with this agreement of $244,000 and $155,000 for the three months ended September 30, 2026 and 2025, respectively, and $452,000 and $359,000 for the nine months ended September 30, 2026 and 2025, respectively.
The Company also makes payments under the current research agreement with USC on a quarterly basis as actual expenses are incurred. As of September 30, 2026, the Company was obligated to pay USC up to $4.3 million for work to be performed during the remaining term. The Company recorded research and development expense in connection with work performed under the agreement of $271,000 and $261,000 for the three months ended September 30, 2026 and 2025, respectively, and $1.2 million and $1.1 million for the nine months ended September 30, 2026 and 2025, respectively.
12. OTHER LIABILITIES:
Other liabilities consist of the following (in thousands):
|
|
|
|
|
|
|
|
|
|
|
September 30, 2026 |
|
|
December 31, 2025 |
|
Long-term lease liabilities |
|
$ |
16,296 |
|
|
$ |
19,217 |
|
Long-term taxes payable |
|
|
15,749 |
|
|
|
15,749 |
|
Other long-term liabilities |
|
|
1,255 |
|
|
|
1,280 |
|
Other liabilities |
|
$ |
33,300 |
|
|
$ |
36,246 |
|
See Notes 9 and 20 for further explanation on long-term lease liabilities and long-term taxes payable, respectively.
13. EQUITY AND CASH COMPENSATION UNDER THE PPG AGREEMENTS:
On September 22, 2011, the Company entered into an Amended and Restated OLED Materials Supply and Service Agreement with PPG (the New OLED Materials Agreement), which, effective as of October 1, 2011, replaced the original OLED Materials Agreement with PPG. The term of the New OLED Materials Agreement, as amended in February 2021 (the February 2021 amendment), runs through December 31, 2026, and thereafter is automatically renewed for additional one-year terms, unless terminated by the Company by providing prior notice of one year or terminated by PPG by providing prior notice of two years. The New OLED Materials Agreement contains provisions that are substantially similar to those of the original OLED Materials Agreement. Under the New OLED Materials Agreement, PPG continues to assist the Company in developing its proprietary OLED materials and supplying the Company with those materials for evaluation purposes and for resale to its customers.
Under the New OLED Materials Agreement, the Company compensates PPG on a cost-plus basis for the services provided during each calendar quarter. The Company is required to pay for some of these services in all cash. Up to 50% of the remaining services are payable, at the Company’s sole discretion, in cash or shares of the Company’s common stock, with the balance payable in cash. The actual number of shares of common stock issuable to PPG is determined based on the average closing price for the Company’s common stock during a specified number of days prior to the end of each calendar half-year period ending on March 31 and September 30. If, however, this average closing price is less than $20.00, the Company is required to compensate PPG in cash. No shares have been issued for services rendered by PPG since the inception of the contract.
The Company is also required to reimburse PPG for raw materials used for research and development. The Company records the purchases of these raw materials as a current asset until such materials are used for research and development efforts.
The February 2021 amendment extended the term of the agreement and specified operation and maintenance services to be provided by PPG affiliate, PPG SCM Ireland Limited (PPG SCM), to UDC Ireland, at the Company’s manufacturing site in Shannon, Ireland that UDC Ireland’s wholly-owned subsidiary, OLED Material Manufacturing Limited (OMM), began leasing at such time for the production of OLED materials. OMM purchased the site in September 2023 and the Company amended and restated the February 2021 amendment to reflect OMM’s ownership and PPG SCM’s updated operation and maintenance services after such purchase. Facility improvements have been completed and operations commenced in June 2022. As with the initial New OLED Materials Agreement, the Company compensates PPG on a cost-plus basis for the services provided at the Shannon manufacturing facility.
The Company recorded research and development expense of $3.8 million and $3.9 million for the three months ended September 30, 2026 and 2025, respectively, and $11.8 million and $12.7 million for the nine months ended September 30, 2026 and
2025, respectively, in relation to the cash portion of the reimbursement of expenses and work performed by PPG, excluding amounts paid for commercial chemicals.
14. SHAREHOLDERS’ EQUITY:
Preferred Stock
The Company’s Amended and Restated Articles of Incorporation authorize it to issue up to 5,000,000 shares of $0.01 par value preferred stock with designations, rights and preferences determined from time-to-time by the Company’s Board of Directors. Accordingly, the Company’s Board of Directors is empowered, without shareholder approval, to issue preferred stock with dividend, liquidation, conversion, voting or other rights superior to those of shareholders of the Company’s common stock.
In 1995, the Company issued 200,000 shares of Series A Nonconvertible Preferred Stock (Series A) to American Biomimetics Corporation (ABC) pursuant to a certain Technology Transfer Agreement between the Company and ABC. The Series A shares have a liquidation value of $7.50 per share. Series A shareholders, as a single class, have the right to elect two members of the Company’s Board of Directors. This right has never been exercised. Holders of the Series A shares are entitled to one vote per share on matters which shareholders are generally entitled to vote. The Series A shareholders are not entitled to any dividends. As of September 30, 2026, the Company had issued 200,000 shares of preferred stock (consisting of the 200,000 shares of Series A), all of which were outstanding.
Common Stock
The Company’s Amended and Restated Articles of Incorporation authorize it to issue up to 200,000,000 shares of $0.01 par value common stock. Each share of the Company’s common stock entitles the holder to one vote on all matters to be voted upon by the shareholders. As of September 30, 2026, the Company had issued 49,063,673 shares of common stock, of which 45,279,598 were outstanding.
On April 29, 2025, the Company’s Board of Directors approved a share repurchase program authorizing the Company to purchase up to $100.0 million of its common stock, which was completed during the nine months ended September 30, 2026. On April 28, 2026, the Company’s Board of Directors authorized the repurchase of up to an additional $400.0 million of the Company’s common stock. The repurchase authorizations were effective immediately and permits shares of the Company’s common stock to be repurchased from time to time at management's discretion, through a variety of methods, including a 10b5-1 trading plan, open market purchases, privately negotiated transactions, or transactions otherwise in compliance with Rule 10b-18 under the Securities Exchange Act of 1934, as amended. The repurchase programs have no time limit, do not obligate the Company to acquire a specified number of shares and may be modified, suspended or discontinued at any time at the Company’s discretion. During the nine months ended September 30, 2026, the Company repurchased an aggregate of 2,127,217 shares of its common stock for $192.9 million. During the nine months ended September 30, 2025, the Company repurchased no shares of common stock.
Dividends
During the three months ended September 30, 2026, the Company declared cash dividends of $0.50 per common share, or $23.0 million, and during the nine months ended September 30, 2026, the Company declared cash dividends of $1.50 per common share, or $70.3 million, on the Company's outstanding common stock. The Company paid $22.7 million and $69.4 million of cash dividends during the three and nine months ended September 30, 2026, respectively.
On October 27, 2026, the Company’s Board of Directors declared a fourth quarter dividend of $0.50 per share to be paid on December 31, 2026 to all shareholders of record of the Company’s common stock as of the close of business on December 17, 2026. All future dividends will be subject to the approval of the Company’s Board of Directors.
During the nine months ended September 30, 2026, the Company granted 128,274 shares of restricted stock awards and restricted stock units to employees and non-employees, which had a total fair value of $12.4 million on the respective dates of grant, and will vest over three to five years from the date of grant, provided that the grantee is still an employee of the Company or is still providing services to the Company on the applicable vesting date.
For the three months ended September 30, 2026 and 2025, the Company recorded, as compensation charges related to all restricted stock awards and units granted to employees and non-employees, selling, general and administrative expense of $1.8 million and $1.9 million, respectively, research and development expense of $1.3 million and $1.2 million, respectively, and cost of sales of $383,000 and $429,000, respectively. For the nine months ended September 30, 2026 and 2025, the Company recorded, as compensation charges related to all restricted stock awards and units granted to employees and non-employees, selling, general and administrative expense of $5.6 million and $5.5 million, respectively, research and development expense of $3.9 million and $3.6 million, respectively, and cost of sales of $1.2 million and $1.3 million, respectively.
In connection with the vesting of restricted stock awards and units during the three months ended September 30, 2026 and 2025, 87 and 192 shares, respectively, with aggregate fair values of $7,000 and $28,000, respectively, were withheld in satisfaction of tax withholding obligations and are reflected as a financing activity within the Consolidated Statements of Cash Flows. In connection with the vesting of restricted stock awards and units during the nine months ended September 30, 2026 and 2025, 33,987 and 33,236 shares, respectively, with aggregate fair values of $3.7 million and $5.0 million, respectively, were withheld in satisfaction of tax withholding obligations and are reflected as a financing activity within the Consolidated Statements of Cash Flows.
The Company has granted restricted stock units to non-employee members of the Board of Directors with quarterly vesting over a period of approximately one year. The fair value is equal to the market price of the Company's common stock on the date of grant. The restricted stock units are issued and expense is recognized ratably over the vesting period. For the three months ended September 30, 2026 and 2025, the Company recorded compensation charges for services performed, related to all restricted stock units granted to non-employee members of the Board of Directors, selling, general and administrative expense of $518,000 and $527,000, respectively. Such compensation charges to selling, general and administrative expense were $1.5 million and $1.6 million for the nine months ended September 30, 2026 and 2025. In connection with the vesting of the restricted stock, the Company issued to non-employee members of the Board of Directors 13,660 and 10,250 shares, respectively, during the nine months ended September 30, 2026 and 2025.
Performance Unit Awards
Each performance unit award is subject to both a performance-vesting requirement (either performance-based or market-based) and a service-vesting requirement. The performance-based vesting requirement is tied to EBITDA and cash flow achievement, as measured over a specific performance period. The market-based vesting requirement is tied to the Company's total shareholder return (TSR) relative to the TSR of companies comprising the Nasdaq US Benchmark Components Index, as measured over a three-year performance period. The maximum number of performance units that may vest based on performance is three times the shares granted. Further, if the Company's performance falls below certain thresholds, the performance units will not vest at all.
During the nine months ended September 30, 2026, the Company granted 102,306 performance units, of which 51,156 units are subject to performance-based vesting requirements based on three-year cumulative adjusted EBITDA, 25,575 units are subject to performance-based vesting requirements based on three-year cumulative gross margin and 25,575 units are subject to market-based, TSR vesting requirements. The grant date fair value of the performance unit awards granted was $9.9 million for the nine months ended September 30, 2026, as determined by the Company’s common stock on date of grant for the units with performance-based vesting and a Monte Carlo simulation model used for the units with market-based vesting.
For the three months ended September 30, 2026 and 2025, the Company recorded selling, general and administrative expense of $1.4 million and $1.3 million, respectively, research and development expense of $515,000 and $511,000, respectively, and cost of sales expense of $319,000 and $316,000, respectively, related to the performance units. For the nine months ended September 30, 2026 and 2025, the Company recorded selling, general and administrative expense of $3.7 million and $6.3 million, respectively, research and development expense of $1.4 million and $2.4 million, respectively, and cost of sales expense of $872,000 and $1.5 million, respectively, related to the performance units.
In connection with the vesting of performance units during the nine months ended September 30, 2026 and 2025, 42,440 and 30,875 shares, respectively, with an aggregate fair value of $4.1 million and $4.5 million, respectively, were withheld in satisfaction of tax withholding obligations and are reflected as a financing activity within the Consolidated Statements of Cash Flows.
Employee Stock Purchase Plan
On April 7, 2009, the Board of Directors of the Company adopted an Employee Stock Purchase Plan (ESPP). The ESPP was approved by the Company’s shareholders and became effective on June 25, 2009. The Company has reserved 1,000,000 shares of common stock for issuance under the ESPP. Unless terminated by the Board of Directors, the ESPP will expire when all reserved shares have been issued.
Eligible employees may elect to contribute to the ESPP through payroll deductions during consecutive three-month purchase periods, the first of which began on July 1, 2009. Each employee who elects to participate will be deemed to have been granted an option to purchase shares of the Company’s common stock on the first day of the purchase period. Unless the employee opts out during the purchase period, the option will automatically be exercised on the last day of the period, which is the purchase date, based on the employee’s accumulated contributions to the ESPP. The purchase price will equal 85% of the lesser of the closing price per share of common stock on the first day of the period or the last business day of the period.
Employees may allocate up to 10% of their base compensation to purchase shares of common stock under the ESPP; however, each employee may purchase no more than 12,500 shares on a given purchase date, and no employee may purchase more than $25,000 of common stock under the ESPP during a given calendar year.
During the nine months ended September 30, 2026 and 2025, the Company issued 20,968 and 13,518 shares, respectively, of its common stock under the ESPP, resulting in proceeds of $1.5 million and $1.6 million, respectively.
For the three months ended September 30, 2026 and 2025, the Company recorded charges of $22,000 and $44,000, respectively, to selling, general and administrative expense, $49,000 and $60,000, respectively, to research and development expense, and $65,000 and $82,000, respectively, to cost of sales related to the ESPP equal to the amount of the discount and the value of the look-back feature. For the nine months ended September 30, 2026 and 2025, the Company recorded charges of $84,000 and $114,000, respectively, to selling, general and administrative expense, $153,000 and $161,000, respectively, to research and development expense, and $189,000 and $200,000, respectively, to cost of sales related to the ESPP equal to the amount of the discount and the value of the look-back feature.
Scientific Advisory Board Awards
During the nine months ended September 30, 2026 and 2025, the Company granted a total of 2,520 and 2,070 shares, respectively, of fully vested common stock to non-employee members of the Scientific Advisory Board for services performed in 2025 and 2024, respectively. The fair value of shares issued to members of the Scientific Advisory Board was $300,000 for both nine-month periods.
For the three months ended September 30, 2026 and 2025, the Company recorded as compensation charges related to all restricted stock units granted to non-employee members of the Scientific Advisory Board, whose unvested shares are marked to market each reporting period, research and development expense of $60,000 for both periods. Such compensation charges to research and development expense were $180,000 and $179,000, respectively, for the nine months ended September 30, 2026 and 2025.
17. RETIREMENT PLAN BENEFIT LIABILITY:
On March 18, 2010, the Human Capital Committee and the Board of Directors of the Company approved and adopted the Universal Display Corporation Supplemental Executive Retirement Plan (SERP). The SERP is currently unfunded and includes salary and bonus as part of the plan. The purpose of the SERP is to provide certain of the Company’s key employees with supplemental pension benefits following a cessation of their employment and to encourage their continued employment with the Company. As of September 30, 2026, there were seven participants in the SERP. In December 2022, one of the participants retired and monthly SERP benefit payments commenced in January 2023. The total SERP benefit payments for both nine months ended September 30, 2026 and 2025 were $1.5 million.
The Company records amounts relating to the SERP based on calculations that incorporate various actuarial and other assumptions, including discount rates, rate of compensation increases, retirement dates and life expectancies. The net periodic costs are recognized as employees render the services necessary to earn the SERP benefits.
increase in the carrying value of one of the Company's minority equity investments. There are no indicators against the realizability of the remaining net deferred tax asset.
On December 27, 2018, the Korean Supreme Court, citing prior cases, held that only royalties paid with respect to Korean registered patents are considered Korean source income and subject to Korean withholding tax under the applicable law and interpretation of the Korea-U.S. Tax Treaty. The Company has incurred Korean withholding tax of $14.9 million for each of the years ended December 31, 2018, through December 31, 2022. Based on the Korean Supreme Court decision, a tax refund request on behalf of the Company was filed with the Korean National Tax Service (KNTS) for the period from January 1, 2018, to December 31, 2022. The Company received a formal rejection from the KNTS, and in May 2022 filed an appeal with the Korean Tax Tribunal. On December 18, 2023, the Company received a formal rejection from the Tax Tribunal. Anticipating the rejection of the appeal, in September 2023 the Company filed a petition to the District Court.
On September 18, 2025, the Korean Supreme Court issued a decision, changing its long-standing position on the taxation of royalties for patents not registered in Korea. The court held that royalties paid for licensing of a patent constitute Korean source income if the patented technology is actually used in the territory of the Republic of Korea. Based on discussions with a prominent Korean law firm, the Company has been advised that there is still a more likely-than-not chance of success, as the manufacturing and sales process occurs within and without the Republic of Korea. During a court appearance in March 2026, the judge requested additional information from the Korean Tax Authority, regarding what amount of royalties would be considered to be related to use in Korea. The Korean Tax Authority has not produced the requested information and, therefore, the scheduled July 2026 hearing was postponed without a specific future date.
The Company has recorded a long-term receivable of $57.5 million and $53.8 million as of September 30, 2026, and December 31, 2025, respectively, for the receipt of the Korean withholding tax. The Company also recorded a foreign exchange gain of $7.2 million and a foreign exchange loss of $1.9 million for the three months ended September 30, 2026 and 2025, respectively, and a foreign exchange gain of $3.7 million and $2.6 million for the nine months ended September 30, 2026 and 2025, respectively, due to the fluctuation of the Korean won to the U.S. Dollar and resulting remeasurement of this won-denominated receivable. The Company will amend U.S. federal tax returns for the 2018 to 2022 years when the anticipated refund from KNTS is received to offset the additional tax liability. The Company has recorded a long-term payable of $15.7 million as of September 30, 2026 and December 31, 2025, for the estimated amounts due to the U.S. federal government based on the amendment of the Company's U.S. tax returns, indicating that lower withholding amounts were required.
The Company is not subject to examinations by the federal tax authority for the years prior to 2022. The Company's state and foreign tax returns are open for a period of generally three to four years. The Company is currently under IRS tax audit for 2023, California tax audit for 2021 and 2022, and Ireland tax audit for 2022. As of September 30, 2026, no adjustments have been proposed for the U.S. audits and the Irish audit is in the fact gathering stage.
The above estimates may change in the future and upon settlement.
21. REVENUE RECOGNITION:
The Company recognizes revenue in accordance with ASC Topic 606, Revenue from Contracts with Customers (Topic 606). The standard establishes the principles that an entity shall apply to report useful information to users of financial statements about the nature, amount, timing, and uncertainty of revenue and cash flows from a contract with a customer.
For both three months ended September 30, 2026 and 2025, the Company recorded 97% of its revenue from OLED related sales and 3% from the providing of services through Adesis. For the nine months ended September 30, 2026 and 2025, the Company recorded 97% and 96%, respectively, of its revenue from OLED related sales and 3% and 4%, respectively, from the providing of services through Adesis.
Contract Balances
ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
The following discussion and analysis of our financial condition and results of operations should be read in conjunction with the unaudited Consolidated Financial Statements and related notes above.
CAUTIONARY STATEMENT
CONCERNING FORWARD-LOOKING STATEMENTS
This discussion and analysis contains some “forward-looking statements.” Forward-looking statements concern possible or assumed future results of operations, including descriptions of our business strategies and customer relationships. These statements often include words such as “believe,” “expect,” “anticipate,” “intend,” “plan,” “estimate,” “seek,” “will,” “may” or similar expressions. These statements are based on assumptions that we have made in light of our experience in the industry, as well as our perceptions of historical trends, current conditions, expected future developments and other factors that we believe are appropriate in these circumstances.
As you read and consider this discussion and analysis, you should not place undue reliance on any forward-looking statements. You should understand that these statements involve substantial risk and uncertainty and are not guarantees of future performance or results. They depend on many factors that are discussed further in the sections entitled (Risk Factors) in our Annual Report on Form 10-K for the year ended December 31, 2025, as supplemented by disclosures in Item 1A of Part II below. Changes or developments in any of these areas could affect our financial results or results of operations and could cause actual results to differ materially from those contemplated in the forward-looking statements.
All forward-looking statements speak only as of the date of this report or the documents incorporated by reference, as the case may be. We do not undertake any duty to update any of these forward-looking statements to reflect events or circumstances after the date of this report or to reflect the occurrence of unanticipated events.
OVERVIEW
We are a leader in the research, development and commercialization of organic light emitting diode (OLED) technologies and materials for use in display applications, such as mobile phones, televisions, monitors, wearables, tablets, portable media devices, notebook computers, personal computers, automotive applications and specialty lighting products. Since 1994, we have been engaged and expect to continue to be primarily engaged, in funding and performing research and development activities relating to OLED technologies and materials, and commercializing these technologies and materials. We derive our revenue primarily from the following:
•sales of OLED materials for evaluation, development and commercial manufacturing;
•intellectual property and technology licensing;
•technology development and support, including third-party collaboration efforts and providing support to third parties for commercialization of their OLED products; and
•contract research services in the areas of chemical materials synthesis research, development and commercialization for non-OLED applications.
Material sales relate to our sale of OLED materials for incorporation into our customers’ commercial OLED products or for their OLED development and evaluation activities. Material sales are generally recognized at the time title passes, which is typically at the time of shipment or at the time of delivery, depending upon the contractual agreement between the parties.
We receive license and royalty payments under certain commercial, development and technology evaluation agreements, some of which are non-refundable advances. These payments may include royalty and license fees made pursuant to license agreements and also license fees included as part of certain commercial supply agreements. These payments are included in the estimate of total contract consideration by customer and recognized as revenue over the contract term based on material units sold at the estimated per unit fee over the life of the contract.
On December 2, 2022, we entered into a commercial patent license agreement with Samsung Display Co., Ltd. (SDC), replacing a previous license agreement that had been in place since 2018. This agreement, which covers the manufacture and sale of specified OLED display materials, was effective as of January 1, 2023 and lasts through the end of 2027 with an additional two-year extension option for SDC. Under this agreement, we are being paid a license fee, which includes quarterly and annual payments over the agreement term. The agreement conveys to SDC the non-exclusive right to use certain of our intellectual property assets for a limited period of time that is less than the estimated life of the assets.
At the same time that we entered into the current commercial license agreement with SDC, we also entered into a material purchase agreement with SDC, which lasts for the same term as the license agreement and is subject to the same extension option. This new material purchase agreement replaced a previous purchase agreement that had been in place since 2018. Under the material purchase agreement, SDC agrees to purchase from us a minimum amount of red and green phosphorescent emitter materials for use in the manufacture of licensed products. This minimum commitment is subject to SDC’s requirements for phosphorescent emitter materials and our ability to meet these requirements over the term of the supplemental agreement.
In 2015, we entered into an OLED patent license agreement and an OLED commercial supply agreement with LG Display Co., Ltd. (LG Display). In 2026, we and LG Display entered into new agreements that extended the terms of these agreements at least through the end of 2030. The patent license agreement provides LG Display a non-exclusive, royalty bearing portfolio license to make and sell OLED displays under their patent portfolio. The patent license calls for minimum annual license fees and additional incremental license fees based on LG Display’s volume of sale of licensed products. The OLED commercial supply agreement provides for the sale of dopant and host materials for use by LG Display.
In 2023, we entered into new long-term, multi-year agreements with BOE Technology Group Co., Ltd. (BOE). Under these agreements, we have granted BOE non-exclusive license rights under various patents owned or controlled by us to manufacture and sell OLED display products. We also supply phosphorescent OLED materials to BOE for use in its licensed products.
In 2019, we entered into an evaluation and commercial supply relationship with Wuhan China Star Optoelectronics Semiconductor Display Technology Co., Ltd. (CSOT). In 2020, we entered into long-term, multi-year agreements with CSOT. Under these agreements, we have granted CSOT non-exclusive license rights under various patents owned or controlled by us to manufacture and sell OLED display products. We also supply phosphorescent OLED materials to CSOT for use in its licensed products.
In 2024, we entered into new long-term, multi-year agreements with Visionox Technology, Inc. (Visionox). Under these agreements, we have granted Visionox non-exclusive license rights under various patents owned or controlled by us to manufacture and sell OLED display products. Additionally, we supply phosphorescent OLED materials to Visionox for use in its licensed products.
In 2025, we entered into long-term, multi-year OLED patent license and material purchase agreements with Tianma Microelectronics Co., Ltd. (Tianma). Under the agreements, we have granted Tianma non-exclusive license rights under various patents owned or controlled by us to manufacture and sell OLED display products. Additionally, we supply phosphorescent OLED materials to Tianma for use in its licensed products.
In 2016, we acquired Adesis, Inc. (Adesis) which has operations in New Castle and Wilmington, Delaware. Adesis is a contract development and manufacturing organization (CDMO) that provides support services on a contractual basis to third-party customers in the OLED, pharma, biotech, catalysis and other industries. As of September 30, 2026, Adesis employed a team of 136 research scientists, chemists, engineers and laboratory technicians. Prior to our acquisition of Adesis, we utilized more than 50% of Adesis’ technology service and production output. We continue to utilize a significant portion of its technology research capacity for the benefit of our OLED technology development, and Adesis uses the remaining capacity to operate as a CDMO by providing contract research services for non-OLED applications to third-party customers in the above-mentioned industries. Contract research services revenue is earned by providing chemical materials synthesis research, development and commercialization for non-OLED applications on a contractual basis for those third-party customers.
In June 2020, we formed a wholly-owned subsidiary, OVJP Corporation (OVJP Corp), operating in California, in order to advance the commercialization of our proprietary Organic Vapor Jet Printing (OVJP) technology, which we now refer to as Universal Vapor Jet Printing (UVJP). In December 2024, we announced the closure of the OVJP Corp facility in California and the relocation of UVJP operations. UVJP operations are now conducted through our Singapore subsidiary, Universal Vapor Jet Corporation Pte. Ltd. (UVJC), and at our Tech and Innovation Center in New Jersey. While we continue to focus on the long-term opportunity in the large-area display market for UVJP, the industry’s current focus is on the growing demand for IT capacity. Our UVJC subsidiary continues to assess additional market opportunities where this technology may be transformative, and in October 2026 UVJC launched NovaJet, the first commercial system built on the UVJP platform.
In February 2021, we announced the establishment of a new manufacturing site in Shannon, Ireland and an agreement between UDC Ireland Limited and PPG for the production of our OLED materials. The Shannon manufacturing facility became operational in June 2022 and we purchased the site during September 2023. The Shannon manufacturing facility provides incremental manufacturing capacity to meet our expanding production needs, and allows for the geographical diversification of our manufacturing base for the world-wide distribution of our materials.
We also generate technology development and support revenue earned from development and technology evaluation agreements and commercialization assistance fees.
We anticipate fluctuations in our annual and quarterly results of operations due to uncertainty regarding, among other factors:
•the timing, cost and volume of sales of our OLED materials;
•the timing of our receipt of license fees and royalties, as well as fees for future technology development and evaluation;
•the timing and magnitude of expenditures we may incur in connection with our ongoing research and development and patent-related activities; and
•the timing and financial consequences of our formation of new business relationships and alliances.
RESULTS OF OPERATIONS
Comparison of the Three Months Ended September 30, 2026 and 2025
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended September 30, |
|
|
|
|
|
|
2026 |
|
|
2025 |
|
|
Increase (Decrease) |
|
REVENUE: |
|
|
|
|
|
|
|
|
|
Material sales |
|
$ |
79,709 |
|
|
$ |
82,634 |
|
|
$ |
(2,925 |
) |
Royalty and license fees |
|
|
75,495 |
|
|
|
53,317 |
|
|
|
22,178 |
|
Contract research services |
|
|
5,228 |
|
|
|
3,662 |
|
|
|
1,566 |
|
Total revenue |
|
|
160,432 |
|
|
|
139,613 |
|
|
|
20,819 |
|
COST OF SALES |
|
|
43,077 |
|
|
|
35,491 |
|
|
|
7,586 |
|
Gross margin |
|
|
117,355 |
|
|
|
104,122 |
|
|
|
13,233 |
|
OPERATING EXPENSES: |
|
|
|
|
|
|
|
|
|
Research and development |
|
|
36,347 |
|
|
|
36,336 |
|
|
|
11 |
|
Selling, general and administrative |
|
|
20,892 |
|
|
|
18,039 |
|
|
|
2,853 |
|
Amortization of acquired technology and other intangible assets |
|
|
3,372 |
|
|
|
4,553 |
|
|
|
(1,181 |
) |
Patent costs |
|
|
2,795 |
|
|
|
1,886 |
|
|
|
909 |
|
Royalty and license expense |
|
|
244 |
|
|
|
170 |
|
|
|
74 |
|
Total operating expenses |
|
|
63,650 |
|
|
|
60,984 |
|
|
|
2,666 |
|
OPERATING INCOME |
|
|
53,705 |
|
|
|
43,138 |
|
|
|
10,567 |
|
Interest income, net |
|
|
8,196 |
|
|
|
10,046 |
|
|
|
(1,850 |
) |
Other income, net |
|
|
37,268 |
|
|
|
952 |
|
|
|
36,316 |
|
Interest and other income, net |
|
|
45,464 |
|
|
|
10,998 |
|
|
|
34,466 |
|
INCOME BEFORE INCOME TAXES |
|
|
99,169 |
|
|
|
54,136 |
|
|
|
45,033 |
|
INCOME TAX EXPENSE |
|
|
(20,223 |
) |
|
|
(10,111 |
) |
|
|
(10,112 |
) |
NET INCOME |
|
$ |
78,946 |
|
|
$ |
44,025 |
|
|
$ |
34,921 |
|
Revenue
Our total material sales were $79.7 million for the three months ended September 30, 2026, as compared to $82.6 million for the three months ended September 30, 2025, a decrease of 4% with an increase in unit material volume of 9%. The decrease in material sales was primarily due to changes in customer mix and a $4.8 million unfavorable period-over-period change in the cumulative catch-up adjustment, primarily attributable to material fees as described below, partially offset by higher unit material volume.
•Green emitter sales for the three months ended September 30, 2026, which include our yellow-green emitters, were $60.9 million as compared to $64.6 million for the three months ended September 30, 2025, with unit material volumes increasing by 5%.
•Red emitter sales for the three months ended September 30, 2026 were $18.9 million as compared to $16.8 million for the three months ended September 30, 2025, with unit material volumes increasing by 25%.
Revenue from royalty and license fees was $75.5 million for the three months ended September 30, 2026 as compared to $53.3 million for the three months ended September 30, 2025, an increase of 42%. The increase in royalty and license fees was primarily the result of a $9.5 million out-of-period adjustment during the three months ended September 30, 2025 that reduced royalty and license fees, higher unit material volume and changes in customer mix.
The total cumulative catch-up adjustment recorded to revenue arising from changes in estimates of transaction price, net was a reduction of $3.5 million for the three months ended September 30, 2026 as compared to a net increase of $1.3 million for the three months ended September 30, 2025. For the three months ended September 30, 2026, the adjustment resulted from a decrease in the average price per gram, primarily due to product mix changes and higher anticipated demand forecasted over the respective remaining lives of certain customer contracts. For the three months ended September 30, 2025, the adjustment resulted from an increase in the average price per gram, primarily due to lower anticipated demand from certain customers over the respective remaining lives of their contracts.
Revenue from contract research services consists of revenue earned by Adesis, which provides support services on a contractual basis to third-party customers in the pharma, biotech, catalysis and other industries. Contract research services revenue was $5.2 million for the three months ended September 30, 2026 as compared to $3.7 million for the three months ended September 30, 2025, an increase of 43%. The increase in contract research services revenue was primarily due to increased specialty manufacturing customer demand at Adesis during the three months ended September 30, 2026.
Cost of sales
Cost of sales for the three months ended September 30, 2026 increased by $7.6 million as compared to the three months ended September 30, 2025, primarily due to higher sales volume, Adesis' cost of sales, and a $1.1 million increase in inventory reserve expense. As a result of the increase in revenue from royalty and license fees, partially offset by the increase in the cost of sales, gross margin for the three months ended September 30, 2026 increased by $13.2 million as compared to the three months ended September 30, 2025, with gross margin as a percentage of revenue decreasing to 73% from 75%.
Research and development
Research and development expenses were $36.3 million for both three months ended September 30, 2026 and 2025.
Selling, general and administrative
Selling, general and administrative expenses increased to $20.9 million for the three months ended September 30, 2026, as compared to $18.0 million for the three months ended September 30, 2025. The increase in selling, general and administrative expenses was primarily due to an increase in employee-related costs and consulting expenses.
Amortization of acquired technology and other intangible assets
Amortization of acquired technology and other intangible assets decreased to $3.4 million for the three months ended September 30, 2026 as compared to $4.6 million for the three months ended September 30, 2025. The decrease in amortization of acquired technology and other intangible assets was primarily due to the completion of amortization of the BASF patent portfolio in June 2026, partially offset by the acquisition of the Merck KGaA patent portfolio in January 2026. See Note 7 in Notes to Consolidated Financial Statements for further discussion.
Patent costs
Patent costs increased to $2.8 million for the three months ended September 30, 2026, as compared to $1.9 million for the three months ended September 30, 2025. The results in the current quarter reflected higher internal prosecution related costs.
Royalty and license expense
Royalty and license expense increased to $244,000 for the three months ended September 30, 2026, as compared to $170,000 for the three months ended September 30, 2025.
Interest and other income, net
Interest income, net was $8.2 million for the three months ended September 30, 2026, as compared to $10.0 million for the three months ended September 30, 2025. The decrease in interest income, net was primarily attributable to lower bond yields and reduced average investment balances on available-for-sale investments compared with the same period in 2025.
Other income, net primarily consisted of net investment gains and losses, net exchange gains and losses on foreign currency transactions and rental income. We recorded other income, net of $37.3 million for the three months ended September 30, 2026 as compared to other income, net of $952,000 for the three months ended September 30, 2025. The increase in other income, net was due to a $28.9 million increase in the carrying value of our minority equity investment portfolio and a $7.2 million foreign exchange gain during the three months ended September 30, 2026 as compared to a $3.0 million investment gain on our marketable equity securities portfolio, partially offset by a $1.9 million foreign exchange loss during the three months ended September 30, 2025. Net exchange gains and losses on foreign currency are primarily caused by the fluctuation in the Korean won to the U.S. Dollar exchange rate and resulting remeasurement of a Korean won-denominated withholding tax receivable.
Income tax expense
We are subject to income taxes in the United States and foreign jurisdictions. The effective income tax rate was 20.4% and 18.7% for the three months ended September 30, 2026 and 2025, respectively, and we recorded income tax expense of $20.2 million and $10.1 million, respectively, for those periods.
Comparison of the Nine Months Ended September 30, 2026 and 2025
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Nine Months Ended September 30, |
|
|
|
|
|
|
2026 |
|
|
2025 |
|
|
Increase (Decrease) |
|
REVENUE: |
|
|
|
|
|
|
|
|
|
Material sales |
|
$ |
229,649 |
|
|
$ |
257,439 |
|
|
$ |
(27,790 |
) |
Royalty and license fees |
|
|
210,917 |
|
|
|
202,553 |
|
|
|
8,364 |
|
Contract research services |
|
|
14,234 |
|
|
|
17,692 |
|
|
|
(3,458 |
) |
Total revenue |
|
|
454,800 |
|
|
|
477,684 |
|
|
|
(22,884 |
) |
COST OF SALES |
|
|
115,988 |
|
|
|
112,828 |
|
|
|
3,160 |
|
Gross margin |
|
|
338,812 |
|
|
|
364,856 |
|
|
|
(26,044 |
) |
OPERATING EXPENSES: |
|
|
|
|
|
|
|
|
|
Research and development |
|
|
106,567 |
|
|
|
107,594 |
|
|
|
(1,027 |
) |
Selling, general and administrative |
|
|
59,489 |
|
|
|
55,493 |
|
|
|
3,996 |
|
Amortization of acquired technology and other intangible assets |
|
|
14,679 |
|
|
|
13,646 |
|
|
|
1,033 |
|
Patent costs |
|
|
7,520 |
|
|
|
6,380 |
|
|
|
1,140 |
|
Royalty and license expense |
|
|
453 |
|
|
|
401 |
|
|
|
52 |
|
Total operating expenses |
|
|
188,708 |
|
|
|
183,514 |
|
|
|
5,194 |
|
OPERATING INCOME |
|
|
150,104 |
|
|
|
181,342 |
|
|
|
(31,238 |
) |
Interest income, net |
|
|
25,388 |
|
|
|
29,883 |
|
|
|
(4,495 |
) |
Other income, net |
|
|
29,974 |
|
|
|
6,905 |
|
|
|
23,069 |
|
Interest and other income, net |
|
|
55,362 |
|
|
|
36,788 |
|
|
|
18,574 |
|
INCOME BEFORE INCOME TAXES |
|
|
205,466 |
|
|
|
218,130 |
|
|
|
(12,664 |
) |
INCOME TAX EXPENSE |
|
|
(41,203 |
) |
|
|
(42,397 |
) |
|
|
1,194 |
|
NET INCOME |
|
$ |
164,263 |
|
|
$ |
175,733 |
|
|
$ |
(11,470 |
) |
Revenue
Our total material sales were $229.6 million for the nine months ended September 30, 2026, as compared to $257.4 million for the nine months ended September 30, 2025, a decrease of 11% with a decrease in unit material volume of 2%. The decrease in material sales was primarily due to changes in customer mix, an $8.5 million unfavorable period-over-period change in the cumulative catch-up adjustment for material sales and lower unit material volume. The $8.5 million unfavorable period-over-period change in the cumulative catch-up adjustment was primarily attributable to product mix changes forecasted over the respective remaining lives of certain customer contracts.
•Green emitter sales for the nine months ended September 30, 2026, which include our yellow-green emitters, were $175.8 million as compared to $191.7 million for the nine months ended September 30, 2025, with unit material volumes decreasing by 1%.
•Red emitter sales for the nine months ended September 30, 2026 were $53.6 million as compared to $62.2 million for the nine months ended September 30, 2025, with unit material volumes decreasing by 4%.
Revenue from royalty and license fees was $210.9 million for the nine months ended September 30, 2026 as compared to $202.6 million for the nine months ended September 30, 2025, an increase of 4%. The increase in royalty and license fees for the nine months ended September 30, 2026 was primarily the result of an $11.1 million favorable period-over-period change in the cumulative catch-up adjustment for royalty and license fees and a $7.1 million out-of-period adjustment that reduced royalty and license fees in the prior-year period, partially offset by lower unit material volume and changes in customer mix. The $11.1 million favorable period-over-period change in the cumulative catch-up adjustment was primarily attributable to an increase in the average royalty and license fees price per gram due to lower anticipated demand from certain customers over the respective remaining lives of their contracts.
The total cumulative catch-up adjustment recorded to revenue arising from changes in estimates of transaction price, net was an increase of $6.5 million for the nine months ended September 30, 2026 as compared to a net increase of $3.9 million for the nine months ended September 30, 2025.
Revenue from contract research services consists of revenue earned by Adesis. Contract research services revenue was $14.2 million for the nine months ended September 30, 2026 as compared to $17.7 million for the nine months ended September 30, 2025, a decrease of 20%. The decrease in contract research services revenue was primarily due to decreased specialty manufacturing customer demand at Adesis during the nine months ended September 30, 2026.
Cost of sales
Cost of sales for the nine months ended September 30, 2026 increased by $3.2 million as compared to the nine months ended September 30, 2025, primarily due to product mix changes and a $1.4 million increase in inventory reserve expense, partially offset by lower sales volume and Adesis' cost of sales. As a result of the decrease in revenue from material sales, partially offset by the increase in revenue from royalty and license fees, gross margin for the nine months ended September 30, 2026 decreased by $26.0 million as compared to the nine months ended September 30, 2025, with gross margin as a percentage of revenue decreasing to 74% from 76%.
Research and development
Research and development expenses decreased to $106.6 million for the nine months ended September 30, 2026, as compared to $107.6 million for the nine months ended September 30, 2025. The decrease in research and development expenses was primarily due to a decrease in stock-based compensation and consulting expenses, partially offset by an increase in development activity.
Selling, general and administrative
Selling, general and administrative expenses increased to $59.5 million for the nine months ended September 30, 2026, as compared to $55.5 million for the nine months ended September 30, 2025. The increase in selling, general and administrative expenses was primarily due to an increase in employee-related costs and consulting expenses, partially offset by a decrease in stock-based compensation.
Amortization of acquired technology and other intangible assets
Amortization of acquired technology and other intangible assets increased to $14.7 million for the nine months ended September 30, 2026 as compared to $13.6 million for the nine months ended September 30, 2025. The increase in amortization of acquired technology and other intangible assets was primarily due to the acquisition of the Merck KGaA patent portfolio in January 2026, partially offset by the completion of amortization of the BASF patent portfolio in June 2026. See Note 7 in Notes to Consolidated Financial Statements for further discussion.
Patent costs
Patent costs increased to $7.5 million for the nine months ended September 30, 2026, as compared to $6.4 million for the nine months ended September 30, 2025. The results in the current year reflected higher internal prosecution related costs.
Royalty and license expense
Royalty and license expense increased to $453,000 for the nine months ended September 30, 2026, as compared to $401,000 for the nine months ended September 30, 2025.
Interest and other income, net
Interest income, net was $25.4 million for the nine months ended September 30, 2026, as compared to $29.9 million for the nine months ended September 30, 2025. The decrease in interest income, net was primarily attributable to lower bond yields and reduced average investment balances on available-for-sale investments compared with the same period in 2025.
Other income, net primarily consisted of net investment gains and losses, net exchange gains and losses on foreign currency transactions and rental income. We recorded other income, net of $30.0 million for the nine months ended September 30, 2026 as compared to other income, net of $6.9 million for the nine months ended September 30, 2025. The increase in other income, net was primarily due to a $28.5 million net increase in the carrying value of our minority equity investment portfolio and a $3.7 million foreign exchange gain, partially offset by a $3.4 million investment loss on our marketable equity securities portfolio during the nine months ended September 30, 2026 as compared to a $3.0 million investment gain on our marketable equity securities portfolio and a $2.6 million foreign exchange gain during the nine months ended September 30, 2025. Net exchange gains and losses on foreign currency are primarily caused by the fluctuation in the Korean won to the U.S. Dollar exchange rate and resulting remeasurement of a Korean won-denominated withholding tax receivable.
Income tax expense
We are subject to income taxes in the United States and foreign jurisdictions. The effective income tax rate was 20.1% and 19.4% for the nine months ended September 30, 2026 and 2025, respectively, and we recorded income tax expense of $41.2 million and $42.4 million, respectively, for those periods.
Liquidity and Capital Resources
Our principal sources of liquidity are our cash and cash equivalents and short-term investments. As of September 30, 2026, we had cash and cash equivalents of $93.4 million, short-term investments of $340.0 million, and long-term U.S. Government bonds investments of $394.6 million for a total of $828.0 million. This compares to cash and cash equivalents of $138.4 million, short-term investments of $464.0 million, and long-term U.S. Government bond investments of $353.0 million for a total of $955.4 million as of December 31, 2025.
Cash provided by operating activities for the nine months ended September 30, 2026 was $234.1 million resulting from $164.3 million of net income, $37.2 million from non-cash items including depreciation, stock-based compensation, amortization of intangibles and investment gains, net, and a $32.6 million increase due to changes in our operating assets and liabilities. Changes in our operating assets and liabilities related to a decrease in accounts receivable of $30.8 million, an increase in deferred revenue of $15.1 million and a decrease in inventory of $4.0 million, partially offset by an increase in other assets of $11.5 million, a decrease in other liabilities of $3.9 million and a decrease in accounts payable and accrued expenses of $1.9 million. The decrease in accounts receivable during the nine months ended September 30, 2026 was primarily due to the timing of material shipments as well as license fee payments from certain customers. The increase in deferred revenue during the nine months ended September 30, 2026 was primarily due to the timing of customer payments and revenue recognition.
Cash provided by operating activities for the nine months ended September 30, 2025 was $179.7 million resulting from $175.7 million of net income and $53.1 million from non-cash items including stock-based compensation, depreciation and amortization of intangibles, partially offset by a $49.1 million reduction due to changes in our operating assets and liabilities. Changes in our operating assets and liabilities related to an increase in other assets of $49.3 million, an increase in inventory of $29.7 million, a decrease in deferred revenue of $8.7 million and a decrease in other liabilities of $1.1 million, partially offset by a decrease in accounts receivable of $39.4 million and an increase in accounts payable of $304,000. The increase in other assets during the nine months ended September 30, 2025 was primarily due to an increase in unbilled receivables from certain customers. The decrease in accounts receivable during the nine months ended September 30, 2025 was primarily due to the timing of material shipments as well as license fee payments from certain customers. The increase in inventory during the nine months ended September 30, 2025 was primarily due to purchases of certain strategic raw materials.
Cash used in investing activities was $10.4 million for the nine months ended September 30, 2026, as compared to cash used in investing activities of $85.0 million for the nine months ended September 30, 2025. The decrease in cash used in investing activities was due to timing of maturities and purchases of investments resulting in net sales and maturities of $47.1 million for the nine months ended September 30, 2026, as compared to net purchases of $44.6 million for the nine months ended September 30, 2025, partially offset by an increase in purchases of intangibles and property and equipment of $17.1 million. The increase in the purchases of intangibles during the nine months ended September 30, 2026 was primarily due to the acquisition of the Merck KGaA patent portfolio in January 2026.
Cash used in financing activities was $268.6 million for the nine months ended September 30, 2026, as compared to $72.1 million for the nine months ended September 30, 2025. The increase was due to an increase in the repurchases of common stock, inclusive of excise tax, of $193.0 million, an increase in the cash payment of dividends in the current year of $5.1 million and a decrease in the proceeds from issuance of common stock of $102,000, partially offset by a decrease in the payment of withholding taxes related to stock-based compensation to employees of $1.7 million.
Working capital was $781.2 million as of September 30, 2026, as compared to $979.0 million as of December 31, 2025. The decrease was primarily due to decreases in short-term investments, cash and cash equivalents and accounts receivable.
We anticipate, based on our internal forecasts and assumptions relating to our operations (including, among others, assumptions regarding our working capital requirements, the progress of our research and development efforts, the availability of sources of funding for our research and development work, and the timing and costs associated with the preparation, filing, prosecution, maintenance, defense and enforcement of our patents and patent applications), that we have sufficient cash, cash equivalents and short-term investments to meet our obligations for at least the next twelve months.
Additional funding may be required in the future for research, development and commercialization of our OLED technologies and materials, to obtain, maintain and enforce patents respecting these technologies and materials, and for working capital and other purposes, the timing and amount of which are difficult to ascertain. We believe that potential additional financing sources for us include long-term and short-term borrowings and public and private sales of our equity and debt securities. There can be no assurance that additional funds will be available to us when needed, on commercially reasonable terms or at all, particularly in the current economic environment.
Critical Accounting Policies and Estimates
The discussion and analysis of our financial condition and results of operations is based on our Consolidated Financial Statements, which have been prepared in accordance with U.S. generally accepted accounting principles. The preparation of these Consolidated Financial Statements requires us to make estimates and judgments that affect our reported assets and liabilities, revenues and expenses, and other financial information. Actual results may differ significantly from our estimates under other assumptions and conditions.
We believe that our accounting policies related to revenue recognition and deferred revenue, inventories, and income taxes are our “critical accounting policies” as contemplated by the SEC.
Refer to our Annual Report on Form 10-K for the year ended December 31, 2025, for additional discussion of our critical accounting policies.
Contractual Obligations
Refer to our Annual Report on Form 10-K for the year ended December 31, 2025 for a discussion of our contractual obligations.
Off-Balance Sheet Arrangements
As of September 30, 2026, we had no off-balance sheet arrangements in the nature of guarantee contracts, retained or contingent interests in assets transferred to unconsolidated entities (or similar arrangements serving as credit, liquidity or market risk support to unconsolidated entities for any such assets), or obligations (including contingent obligations) arising out of variable interests in unconsolidated entities providing financing, liquidity, market risk or credit risk support to us, or that engage in leasing, hedging or research and development services with us.
ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
We do not utilize financial instruments for trading purposes and hold no derivative financial instruments, other financial instruments or derivative commodity instruments that could expose us to significant market risk other than our investments disclosed in “Fair Value Measurements” in Note 4 to the Consolidated Financial Statements. We generally invest in investment grade financial instruments to reduce our exposure related to investments. Our primary market risk exposure with regard to such financial instruments is to changes in interest rates, which would impact interest income earned on investments. However, based upon the conservative nature of our investment portfolio and current experience, we do not believe a decrease in investment yields would have a material negative effect on our interest income.
Substantially all our revenue is derived from outside of North America and primarily denominated in U.S. dollars and therefore we bear no significant foreign exchange risk from routine customer sales transactions. However, due to a withholding tax receivable denominated in Korean won, we do bear foreign exchange risk from fluctuations in the Korean won to U.S. dollar exchange rate and resulting remeasurement.
ITEM 4. CONTROLS AND PROCEDURES
Evaluation of Disclosure Controls and Procedures
Our management, with the participation of our Chief Executive Officer and Chief Financial Officer, evaluated the effectiveness of our disclosure controls and procedures as of September 30, 2026. Based on that evaluation, the Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures, as of the end of the period covered by this report, are effective to provide reasonable assurance that the information required to be disclosed by us in reports filed or submitted under the Securities Exchange Act of 1934, as amended, is (i) recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms, and (ii) accumulated and communicated to our management, including the Chief Executive Officer and Chief Financial Officer, as appropriate to allow timely decisions regarding disclosure. However, a controls system, no matter how well designed and operated, cannot provide absolute assurance that the objectives of the controls system are met, and no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within a company have been detected
Changes in Internal Control over Financial Reporting
There were no changes in our internal control over financial reporting during the quarter ended September 30, 2026 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.
PART II – OTHER INFORMATION
ITEM 1. LEGAL PROCEEDINGS
Patent Related Challenges and Oppositions
Each major jurisdiction in the world that issues patents provides both third parties and applicants an opportunity to seek a further review of an issued patent. The process for requesting and considering such reviews is specific to the jurisdiction that issued the patent in question, and generally does not provide for claims of monetary damages or a review of specific claims of infringement. The conclusions made by the reviewing administrative bodies tend to be appealable and generally are limited in scope and applicability to the specific claims and jurisdiction in question.
We believe that opposition proceedings are frequently commenced in the ordinary course of business by third parties who may believe that one or more claims in a patent do not comply with the technical or legal requirements of the specific jurisdiction in which the patent was issued. We view these proceedings as reflective of its goal of obtaining the broadest legally permissible patent coverage permitted in each jurisdiction. Once a proceeding is initiated, as a general matter, the issued patent continues to be presumed valid until the jurisdiction’s applicable administrative body issues a final non-appealable decision. Depending on the jurisdiction, the outcome of these proceedings could include affirmation, denial or modification of some or all of the originally issued claims. We believe that as OLED technology becomes more established and its patent portfolio increases in size, so will the number of these proceedings.
ITEM 1A. RISK FACTORS
There have been no material changes to the risk factors previously discussed in Part I, Item 1A “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2025.
ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS
Purchases of Equity Securities by the Issuer and Affiliated Purchasers
On April 28, 2026, our Board of Directors authorized the repurchase of up to an additional $400.0 million of our common stock. The repurchase authorization was effective immediately and permitted shares of the Company’s common stock to be repurchased from time to time at management's discretion, through a variety of methods, including a 10b5-1 trading plan, open market purchases, privately negotiated transactions, or transactions otherwise in compliance with Rule 10b-18 under the Securities Exchange Act of 1934, as amended. The repurchase program has no time limit, does not obligate the Company to acquire a specified number of shares and can be modified, suspended or discontinued at any time at the Company’s discretion.
Share repurchase activity during the three months ended September 30, 2026, was as follows (in thousands, except share and per share data):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Period |
|
Total Number of Shares Purchased |
|
|
Average Price Paid Per Share |
|
|
Total Number of Shares Purchased as Part of Publicly Announced Plans |
|
|
Approximate Dollar Value of Shares that May Yet Be Purchased Under the Plan |
|
July 1 - 31, 2026 |
|
|
341,733 |
|
|
$ |
80.47 |
|
|
|
341,733 |
|
|
$ |
324,255 |
|
August 1 - 31, 2026 |
|
|
288,556 |
|
|
|
86.64 |
|
|
|
288,556 |
|
|
|
299,256 |
|
September 1 - 30, 2026 |
|
|
333,044 |
|
|
|
78.84 |
|
|
|
333,044 |
|
|
|
272,999 |
|
Total |
|
|
963,333 |
|
|
$ |
81.75 |
|
|
|
963,333 |
|
|
$ |
272,999 |
|
ITEM 3. DEFAULTS UPON SENIOR SECURITIES
None.
ITEM 4. MINE SAFETY DISCLOSURES
Not applicable.
ITEM 5. OTHER INFORMATION
Trading Arrangements
During the quarter ended September 30, 2026, none of our directors or executive officers adopted or terminated a “Rule 10b5-1 trading arrangement” or “non-Rule 10b5-1 trading arrangement,” as each term is defined in Item 408(a) of Regulation S-K.
SERP Amendment
On October 27, 2026, the Company’s Board of Directors (the “Board”), on the recommendation of its Human Capital Committee (the “HCC”), adopted Amendment 2026-1 to the SERP (“Amendment 2026-1”). Amendment 2026-1 amended the SERP to change the designated retirement age from age 65 to age 62, and to provide that persons who are at least age 62 but less than age 65 at the time of their qualifying termination or death, and who have at least 15 but less than 20 years of service, will receive prorated benefits as described in Amendment 2026-1. This change affects only one named executive officer participant in the SERP, Mauro Premutico, the Company’s Senior Vice President, Planning, Chief Legal Officer and Secretary, as all other named executive officer participants in the SERP are at least age 65.
Senior Management Severance Program
Also on October 27, 2026, the Board adopted a Senior Management Severance Program (the “SMSP”). Participants in the SERP are not eligible to participate in the SMSP. Thus, the only named executive officer who will participate in the SMSP is Brian Millard, the Company’s Vice President, Chief Financial Officer and Treasurer. Participants in the SMSP are entitled to receive, following termination without cause, including a termination for good reason (both as defined in the SMSP), amounts including the following: (i) earned salary through the termination date; (ii) accrued but unpaid bonus for a completed year; (iii) a severance payment equal to twelve months of base salary plus the full year bonus that would have been earned for the year in which termination occurs based on actual performance as measured at the conclusion of the applicable year. The SMSP benefits shall not duplicate any payments to which the executive may become entitled under the executive’s change in control agreement. The benefits specified in clauses (ii) and (iii) above will vest 25%/year over four years, with the Board having the discretion to accelerate upon a separation event.
ITEM 6. EXHIBITS
The following is a list of the exhibits filed as part of this report. Where so indicated by footnote, exhibits that were previously filed are incorporated by reference. For exhibits incorporated by reference, the location of the exhibit in the previous filing is indicated parenthetically, together with a reference to the filing indicated by footnote.
|
|
|
Exhibit Number |
|
Description |
|
|
|
31.1* |
|
Certifications of Steven V. Abramson, Chief Executive Officer, as required by Rule 13a-14(a) or Rule 15d-14(a) |
|
|
|
31.2* |
|
Certifications of Brian Millard, Chief Financial Officer, as required by Rule 13a-14(a) or Rule 15d-14(a) |
|
|
|
32.1** |
|
Certifications of Steven V. Abramson, Chief Executive Officer, as required by Rule 13a-14(b) or Rule 15d-14(b), and by 18 U.S.C. Section 1350. (This exhibit shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liability of that section. Further, this exhibit shall not be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended.) |
|
|
|
32.2** |
|
Certifications of Brian Millard, Chief Financial Officer, as required by Rule 13a-14(b) or Rule 15d-14(b), and by 18 U.S.C. Section 1350. (This exhibit shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liability of that section. Further, this exhibit shall not be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended.) |
|
|
|
101.INS* |
|
Inline XBRL Instance Document – the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document. |
|
|
|
101.SCH* |
|
Inline XBRL Taxonomy Extension Schema with Embedded Linkbase Documents. |
|
|
|
104 |
|
The cover page of this Quarterly Report on Form 10-Q for the quarter ended September 30, 2026 formatted in Inline XBRL (included in Item 101.INS) |
Explanation of footnotes to listing of exhibits:
|
|
|
* |
|
Filed herewith. |
** |
|
Furnished herewith. |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
|
|
|
|
|
|
UNIVERSAL DISPLAY CORPORATION |
|
|
|
|
|
Date: October 28, 2026 |
|
By: /s/ Brian Millard |
|
|
|
Brian Millard |
|
|
|
Vice President, Chief Financial Officer and Treasurer |
|
|
|
|
|